Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 19/20 | 0.56 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.43 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16898931 | 0.93 | IRAK4 (0.49) | IRAK4 | |
| SCHEMBL16899238 | 0.89 | IRAK4 (0.54) | IRAK4 | |
| SCHEMBL16906699 | 0.89 | IRAK4 (0.69) | IRAK4NTRK1FLT3PRKAA1MAP4K1 | |
| Hydrochloric Acid SCHEMBL16899064 | 0.88 | IRAK4 (0.68) | IRAK4NTRK1FLT3PRKAA1MAP4K1 | |
| Hypochlorous Acid SCHEMBL20787500 | 0.88 | IRAK4 (0.68) | IRAK4NTRK1FLT3PRKAA1MAP4K1 | |
| SCHEMBL16898999 | 0.87 | IRAK4 (0.55) | IRAK4 | |
| SCHEMBL16899159 | 0.86 | IRAK4 (0.48) | IRAK4 | |
| SCHEMBL16898755 | 0.84 | IRAK4 (0.49) | IRAK4 | |
| SCHEMBL16898969 | 0.83 | IRAK4 (0.46) | IRAK4NTRK1FLT3PRKAA1MAP4K1 | |
| SCHEMBL16899199 | 0.83 | IRAK4 (0.48) | IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10160753-B2 | Indazole compounds as IRAK4 inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2018-12-25 | — | — | US | disclosed |
| EP-3092226-A1 | INDAZOLE COMPOUNDS AS IRAK4 INHIBITORS | Aurigene Discovery Technologies Limited (IN) | 2016-11-16 | — | — | EP | disclosed |
| US-20160326151-A1 | Indazole Compounds as IRAK4 Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2016-11-10 | — | — | US | disclosed |
| WO-2015104662-A1 | INDAZOLE COMPOUNDS AS IRAK4 INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10160753-B2 | Indazole compounds as IRAK4 inhibitors | IRAK4, IRAK3, IRAK1 | IRAK4 1/4885NTRK1 2322/4885FLT3 297/4885 |
| US-20160326151-A1 | Indazole Compounds as IRAK4 Inhibitors | IRAK4, IRAK3, IRAK1 | IRAK4 1/4885NTRK1 2322/4885FLT3 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.